Department of Pathology, University of Virginia, Charlottesville, Virginia, USA.
Lab Bacchi, Botucatu, SP, Brazil.
J Cutan Pathol. 2021 Nov;48(11):1367-1378. doi: 10.1111/cup.14077. Epub 2021 Jul 5.
Cutaneous involvement by classic Hodgkin lymphoma (CHL) is an extraordinarily rare phenomenon in the current era. To date, no single large case series of cutaneous involvement by Hodgkin lymphoma has ever been reported in the literature.
A comprehensive search for cases designated "skin" and "Hodgkin" was performed at different institutions between 1990 and 2020. Twenty-five cases were identified, and each case was independently reviewed by at least three board-certified dermatopathologists and/or hematopathologists.
All cases represented examples of systemic CHL with secondary skin dissemination. A single lesion, usually a tumor, nodule or infiltrative plaque was observed in 56% of cases and multiple lesions were present in 28% of cases. Most patients (86%-12/14) had a diagnosis of stage IV disease at first diagnosis. The interval between the clinical (first) diagnosis of HL and the development of skin lesions ranged between 6 and 108 months (average 33.75 months). Comprehensive histopathologic evaluation of these cases (at the initial diagnosis) revealed a diagnosis of classic HL not otherwise specified (NOS) in 60% of cases (15/25), nodular sclerosis type in 24% (6/25), mixed cellularity in 12% (3/25), and lymphocyte depleted in 4% (1/25).
We provide documentation of a large series of CHL with secondary skin involvement in association with CHL with additional clinical, morphologic, and immunophenotypic features.
经典霍奇金淋巴瘤(CHL)皮肤受累在当前时代是一种极其罕见的现象。迄今为止,文献中从未报道过单个大型霍奇金淋巴瘤皮肤受累的病例系列。
在 1990 年至 2020 年期间,在不同机构对指定为“皮肤”和“霍奇金”的病例进行了全面搜索。确定了 25 例病例,由至少三位经过董事会认证的皮肤科医生和/或血液病理学家对每个病例进行独立审查。
所有病例均代表系统性 CHL 伴继发性皮肤播散的例子。56%的病例观察到单个病变,通常是肿瘤、结节或浸润性斑块,28%的病例存在多个病变。大多数患者(86%-12/14)在首次诊断时被诊断为 IV 期疾病。HL 的临床(首次)诊断与皮肤病变发展之间的间隔为 6 至 108 个月(平均 33.75 个月)。对这些病例(在初始诊断时)进行全面的组织病理学评估,发现 60%(15/25)的病例诊断为非特指型经典 HL、24%(6/25)为结节性硬化型、12%(3/25)为混合细胞型和 4%(1/25)为淋巴细胞耗竭型。
我们提供了大量 CHL 与继发性皮肤受累相关的 CHL 病例系列的记录,这些病例具有其他临床、形态学和免疫表型特征。